Chuan Li

Title: Chuan Li: Innovator in Pharmaceutical Research

Introduction

Chuan Li is a prominent inventor based in Tianjin, China. He has made significant contributions to the pharmaceutical field, particularly in the treatment of hyperuricemia and gout. His innovative work has led to the development of a unique compound that addresses these medical conditions.

Latest Patents

Chuan Li holds a patent for a "Carboxylic acid URAT1 inhibitor containing diarylmethane structure, preparation method and use thereof." This invention focuses on a carboxylic acid urate transporter 1 (URAT1) inhibitor, which is crucial for developing medications aimed at treating hyperuricemia and gout. The patent outlines a preparation method and the pharmaceutical composition that includes this compound, showcasing its potential in medical applications.

Career Highlights

Chuan Li is affiliated with the Tianjin Institute of Pharmaceutical Research Co., Ltd. His work at this institute has been instrumental in advancing research and development in the pharmaceutical sector. With a focus on innovative solutions, he has contributed to the creation of effective treatments for prevalent health issues.

Collaborations

Chuan Li has collaborated with notable colleagues, including Wei Liu and Zhixing Zhou. These partnerships have fostered a collaborative environment that enhances research outcomes and drives innovation in pharmaceutical development.

Conclusion

Chuan Li's contributions to the field of pharmaceuticals, particularly through his patent for a URAT1 inhibitor, highlight his role as an innovator in medical research. His work continues to pave the way for advancements in treatments for hyperuricemia and gout.